Perampanel, a selective noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist, is capable of slowing the progression of the amyotrophic lateral sclerosis (ALS) phenotype and increasing the number of anterior horn cells in transgenic mice. Trials of perampanel in epilepsy showed a favorable tolerability profile. In this study we aimed to determine the tolerability and safety of perampanel in patients with ALS.

中文翻译：

---

吡仑帕奈治疗肌萎缩侧索硬化的安全性和耐受性的开放标签试点研究

Perampanel 是一种选择性非竞争性 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸 (AMPA) 拮抗剂，能够减缓肌萎缩侧索硬化 (ALS) 表型的进展并增加前角细胞的数量。转基因小鼠。吡仑帕奈治疗癫痫的试验显示出良好的耐受性。在这项研究中，我们旨在确定吡仑帕奈在 ALS 患者中的耐受性和安全性。